A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer (CA258-0001)
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
March 20, 2026
End Date
February 22, 2031
Awarded By
Bristol-Myers Squibb Company
Start Date
March 20, 2026
End Date
February 22, 2031